Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study. 2013

Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
Section of Psychiatry, Department of Neurosciences, Psychiatric and Anesthesiological Sciences, University of Messina, Messina, Italy. antonio.bruno@unime.it

Pharmacological therapy for fibromyalgia syndrome (FMS) is actually unsatisfactory; analgetic and nonsteroidal anti-inflammatory drugs are not very effective. On the other hand, it is opportune to underline that antidepressant drugs produce positive response on pain in patients with FMS. Furthermore, many studies showed that using variable doses of melatonin (3-6 mg/d) in subjects affected from FMS had significantly been effective on pain, sleep, daytime fatigue, and depression. This study was aimed to evaluate the efficacy of agomelatine on depression, anxiety, cognition, and pain in a sample of drug-free FMS patients. Agomelatine was administered at the single daily dose of 25 mg/d to 15 fibromyalgia "drug-free" female subjects during 12 weeks. Outcome measures included the Hamilton Rating Scale for Depression, the Hamilton Rating Scale for Anxiety, the Zung Self-Rating Depression Scale, the Zung Self-Rating Anxiety Scale, the Visual Analog Scale of Pain, the Quality of Life Index, the Wisconsin Card Sorting Test, the Verbal Fluency Task-Controlled Oral Word Association Test, and the Stroop Color-Word Test. Treatment with agomelatine significantly improved depression, anxiety, and pain in patients with FMS. Regarding executive/cognitive symptoms, treatment with agomelatine did not have a significant impact on the explored neuropsychological domains, although there was a trend toward the improvement of performances. The findings showed that agomelatine was effective and well tolerated in patients with FMS. Further research is needed to fully evaluate the role of agomelatine as a potential pharmacological strategy for the treatment of FMS.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009483 Neuropsychological Tests Tests designed to assess neurological function associated with certain behaviors. They are used in diagnosing brain dysfunction or damage and central nervous system disorders or injury. Aphasia Tests,Cognitive Test,Cognitive Testing,Cognitive Tests,Memory for Designs Test,Neuropsychological Testing,AX-CPT,Behavioral Assessment of Dysexecutive Syndrome,CANTAB,Cambridge Neuropsychological Test Automated Battery,Clock Test,Cognitive Function Scanner,Continuous Performance Task,Controlled Oral Word Association Test,Delis-Kaplan Executive Function System,Developmental Neuropsychological Assessment,Hooper Visual Organization Test,NEPSY,Neuropsychologic Tests,Neuropsychological Test,Paced Auditory Serial Addition Test,Repeatable Battery for the Assessment of Neuropsychological Status,Rey-Osterrieth Complex Figure,Symbol Digit Modalities Test,Test of Everyday Attention,Test, Neuropsychological,Tests, Neuropsychological,Tower of London Test,Neuropsychologic Test,Test, Cognitive,Testing, Cognitive,Testing, Neuropsychological,Tests, Cognitive
D010147 Pain Measurement Scales, questionnaires, tests, and other methods used to assess pain severity and duration in patients or experimental animals to aid in diagnosis, therapy, and physiological studies. Analgesia Tests,Analogue Pain Scale,Formalin Test,McGill Pain Questionnaire,Nociception Tests,Pain Assessment,Pain Intensity,Pain Severity,Tourniquet Pain Test,Visual Analogue Pain Scale,Analog Pain Scale,Assessment, Pain,McGill Pain Scale,Visual Analog Pain Scale,Analgesia Test,Analog Pain Scales,Analogue Pain Scales,Formalin Tests,Intensity, Pain,Measurement, Pain,Nociception Test,Pain Assessments,Pain Intensities,Pain Measurements,Pain Questionnaire, McGill,Pain Scale, Analog,Pain Scale, Analogue,Pain Scale, McGill,Pain Severities,Pain Test, Tourniquet,Questionnaire, McGill Pain,Scale, Analog Pain,Scale, Analogue Pain,Scale, McGill Pain,Severity, Pain,Test, Analgesia,Test, Formalin,Test, Nociception,Test, Tourniquet Pain,Tests, Nociception,Tourniquet Pain Tests
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003071 Cognition Intellectual or mental process whereby an organism obtains knowledge. Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D005260 Female Females
D005356 Fibromyalgia A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95) Diffuse Myofascial Pain Syndrome,Fibrositis,Rheumatism, Muscular,Fibromyalgia, Primary,Fibromyalgia, Secondary,Fibromyalgia-Fibromyositis Syndrome,Fibromyositis-Fibromyalgia Syndrome,Myofascial Pain Syndrome, Diffuse,Fibromyalgia Fibromyositis Syndrome,Fibromyalgia-Fibromyositis Syndromes,Fibromyalgias,Fibromyalgias, Primary,Fibromyalgias, Secondary,Fibromyositis Fibromyalgia Syndrome,Fibromyositis-Fibromyalgia Syndromes,Fibrositides,Muscular Rheumatism,Primary Fibromyalgia,Primary Fibromyalgias,Secondary Fibromyalgia,Secondary Fibromyalgias,Syndrome, Fibromyalgia-Fibromyositis,Syndrome, Fibromyositis-Fibromyalgia,Syndromes, Fibromyalgia-Fibromyositis,Syndromes, Fibromyositis-Fibromyalgia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
March 2014, Pharmacopsychiatry,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
September 2010, BMC musculoskeletal disorders,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
May 2011, BMC musculoskeletal disorders,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
August 2014, Journal of clinical psychopharmacology,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
January 2016, Clinical neuropharmacology,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
January 2016, Clinical neuropharmacology,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
January 2013, Neuropsychiatric disease and treatment,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
September 2009, International clinical psychopharmacology,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
August 2010, Current therapeutic research, clinical and experimental,
Antonio Bruno, and Umberto Micò, and Simona Lorusso, and Nadia Cogliandro, and Gianluca Pandolfo, and Maurizio Caminiti, and Rocco A Zoccali, and Maria R A Muscatello
August 2017, The Australasian journal of dermatology,
Copied contents to your clipboard!